

Investor Presentation: Q4 FY16



- Company Snapshot
- Business Overview
- Core Business Model
- Initiatives for Future Growth
- CRAMS Business
- Group Structure and Manufacturing Facilities
- Revenue Breakup for Q4 FY'16
- **Quarterly Growth Momentum**
- Financial Overview Trends
- Business Trends
- Organization Structure

Disclaimer

This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Company Snapshot


- Present across the entire pharmaceutical manufacturing value chain from active pharmaceutical ingredients (API) to pharmaceutical formulation intermediates (PFI) to finished dosages (FD) manufacturing.
- Manufacturing facilities with approvals from the U.S. FDA, EDQM and other regulators.
- Regulated markets of North America and Europe account for 60% of overall revenue, while the balance comes from quality conscious customers in Latin America, India and ROW countries.
- Entered potentially higher margin products through Auctus Pharma acquisition in 2014 with focus on development of new APIs through in-house R&D.
- Presence in potentially higher margin CRAMS business through 50-50 JV with Ajinomoto Omnichem.
- Ventured into manufacturing and marketing of OTC products to the retail chains in the North American markets
- Acquired Formulation facility in Virginia in the USA, to introduce value added form of existing products and to concentrate into formulation R&D of complex molecules.

Listing information : NSE			
MP (INR) as of 31 st March	120		
Market Cap (INR mn)	25,995		
Market Cap (USD mn)	394		
Outstanding Equity Shares (mn)	216.71		
Face value of equity (INR)	1.0		
52 weeks high/low (INR)	162 / 78		
Bloomberg code	GRAN:IN		
Sector	Pharmaceuticals		


Share Holding Pattern	Sep-15	Dec-15	Mar-16
Promoters Group (%)	48.4	49.5	51.2
Public (%)	51.6	50.5	48.8

Financial Snapshot	FY 14	FY15	FY16
Sales (INR Mn)	10,959	12,937	14,312
EBITDA (INR Mn)	1,626	2,130	2,844
EBITDA Margin	14.8%	16.5%	19.9%
PAT (INR Mn)	752	909	1,185
PAT Margin	6.9%	7.0%	8.3%
Net Worth (INR Mn)	3,557	4,312	6,660
Total Debt (INR Mn)	4,417	4,822	4,741

Business Overview



Core Business Model



Initiatives for Future Growth

New API Division

Auctus Acquisition

G

E

Ν

E

R

C

B

U

S

Ν

Ε

S

S

- Auctus was a loss-making yet high-potential API business
- Significant saving in time for Granules on **growth strategy**.
- Brought **12 molecules** to the table in therapeutic areas such as antihistaminic, anti-hypertensive, antithrombotic, anticonvulsant.
- USFDA approved multipurpose API manufacturing facility in Vizag and an intermediate manufacturing facility in Hyderabad
- The Company's 22 regulatory filings include 8 European filings, 4 USDMFs, 3 South Korean DMFs, 3 IDL China, 2 Health Canada, 1 Italy and 1 Spain.
- **Granules Research Centre**
 - Established in house R&D cell to develop new generic products in a 10,000 sq.ft area in Hyderabad.
 - Presently over 50 scientists are focusing towards complex products.

Granules Pharmaceutical Inc.

- Acquired formulation facility in Virginia ,in the USA, to introduce value added form of existing products and to concentrate into formulation R&D of complex molecules.
- Part of group's the diversification strategy into high value, low volume products
- Primary focus on formulation research and development with a list of 12-14 products the ANDAs for which, will be filed for within the next 2-5 years.

Granules Consumer Healthcare

- Marketing of store brand OTC products with direct relationship with retail outlets in the US $(B \rightarrow B \rightarrow C)$
- Extension of core business with existing products in the initial stage and thereafter continuously increasing
 product offering by introducing new OTC products through new API division.

Foray into Contract Research And Manufacturing Services

 Set up in July 2011 as a 50-50 JV company with Belgium based Omnichem, a part of the Ajinomoto Group. The JV has set up a facility in Vizag SEZ for manufacturing of high-value APIs for Innovators and Brand Leaders on a contract manufacturing basis.

□ JV strategy

To provide a cost effective manufacturing base to innovators for their products when they go off patent
 this will help Omnichem's customers decelerate loss of market share for their brands

D Progress and timelines

- Project is completed and commercial sale has started.
- Supply of API intermediates to Omnichem (JV partner) till the facility is approved by regulatory authorities.
- Currently working on 4-5 products

Growth from CRAMS business


- USFDA / EDQM approvable plant
- Omnichem's established customer base to be major contributor to revenues

Group Structure and Manufacturing Capabilities

	Granules India	\Rightarrow	Incorporated in 1991, this is the only listed entity in the group, with 4 plants located in Hyderabad (Jeedimetla, Bonthapally and Gagillapur) and 1 in Vizag Pharma City
\rightarrow	Granules USA Inc.	\Rightarrow	100% subsidiary, for front-end marketing in the U.S. market
\rightarrow	Granules Biocause	\Rightarrow	A 50-50 joint venture with Chinese-based Hubei Biocause. JV has been operational since 2007 and manufactures Ibuprofen API at a plant located in central China (Jingmen).
\rightarrow	Granules Omnichem	\Rightarrow	A 50-50 joint venture with Ajinomoto OmniChem, to focus on high-value, low-volume APIs and intermediates for the latter's existing customers with a manufacturing facility at Vizag SEZ.
\rightarrow	Granules Pharmaceutical Inc.	\Rightarrow	100% subsidiary with manufacturing setup at Chantilly, USA focused on advanced formulation development.
	Granules Lifesciences	\Rightarrow	100% subsidiary located at Vizag, with multi product API manufacturing facility under construction to focus introduction of on new generic APIs.

Value Chain	Facility Location	Approvals
ΑΡΙ	Bonthapally	U.S. FDA, EDQM, WHO GMP, ISO 14001:2004, OHSAS 18001:2007
Jeedimetla		U.S. FDA, KFDA, TGA, EDQM
	Jingmen, China (Biocause JV)	U.S. FDA, MHRA, EDQM, TGA, KFDA, Health Canada
	Vizag	U.S. FDA, EDQM, KFDA, WHO GMP, Health Canada
	Vizag SEZ (Omnichem JV - CRAMs)	
PFI	Gagillapur	U.S. FDA, EDQM, TGA, GHCA
	Jeedimetla	HHA (Germany)
FD	Gagillapur	U.S. FDA, TGA, GHCA
	Virginia, the USA	Yet to be applied
API Intermediates	Bonthapally (Auctus)	N.A.


Break-up of Q4 FY16 Consolidated Revenue




Quarterly growth momentum till Q4 FY16



Financial Overview – Trends (1/2)




Financial Overview – Trends (2/2)




* Annualized


Business Trends (1/2)



Business Trends (2/2)



Organization Structure



Thank You